Viktória László
YOU?
Author Swipe
View article: Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer
Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer Open
View article: High circulating activin A plasma levels are associated with tumour stage and poor survival in treatment-naive lung squamous cell cancer patients
High circulating activin A plasma levels are associated with tumour stage and poor survival in treatment-naive lung squamous cell cancer patients Open
View article: C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer
C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer Open
Background By being highly involved in the tumor evolution and disease progression of small cell lung cancer (SCLC), Myc family members (C-Myc, L-Myc, and N-Myc) might represent promising targetable molecules. Our aim was to investigate th…
View article: Circulating <scp>FGF18</scp> is decreased in pleural mesothelioma but not correlated with disease prognosis
Circulating <span>FGF18</span> is decreased in pleural mesothelioma but not correlated with disease prognosis Open
Background Pleural mesothelioma (PM) is a relatively rare malignancy with limited treatment options and dismal prognosis. We have previously found elevated FGF18 expression in PM tissue specimens compared with normal mesothelium. The objec…
View article: Laser ablation‐inductively coupled plasma‐mass spectrometry analysis reveals differences in chemotherapeutic drug distribution in surgically resected pleural mesothelioma
Laser ablation‐inductively coupled plasma‐mass spectrometry analysis reveals differences in chemotherapeutic drug distribution in surgically resected pleural mesothelioma Open
Aims Pleural mesothelioma (PM) is a highly aggressive thoracic tumour with poor prognosis. Although reduced tissue drug accumulation is one of the key features of platinum (Pt) resistance, little is known about Pt distribution in human PM.…
View article: Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms
Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms Open
By providing insights into the widely divergent immunologic profiles of LNENs, our results might serve as a basis for the development of novel immunotherapy-related approaches in these devastating malignancies.
View article: Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Trabectedin synergizes with the bcl-2 inhibitor obatoclax in a pleural mesothelioma cell model
View article: Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Table S1: Source, background, histology of the tumor and sensitivity towards trabectedin and cisplatin of all mesothelial and mesothelioma cell models used Supplementary Table S2: Cell death-related genes most differently exp…
View article: Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Trabectedin synergizes with the bcl-2 inhibitor obatoclax in a pleural mesothelioma cell model
View article: Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to systemic therapy. Trabectedin is an antineoplastic agent targeting both the malignant cells and the tumor microenvironment that has been approved for the tre…
View article: Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Figure S1: Sensitivity of pleural mesothelioma cell models to trabectedin and impact of the histological origin Supplementary Figure S2: Impact of trabectedin on the migratory potential of pleural mesothelioma cell models Sup…
View article: Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to systemic therapy. Trabectedin is an antineoplastic agent targeting both the malignant cells and the tumor microenvironment that has been approved for the tre…
View article: Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Figure S1: Sensitivity of pleural mesothelioma cell models to trabectedin and impact of the histological origin Supplementary Figure S2: Impact of trabectedin on the migratory potential of pleural mesothelioma cell models Sup…
View article: Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Table S1: Source, background, histology of the tumor and sensitivity towards trabectedin and cisplatin of all mesothelial and mesothelioma cell models used Supplementary Table S2: Cell death-related genes most differently exp…
View article: Supplementary Figure S2 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Figure S2 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Figure S2. C-reactive protein (CRP) levels of MPM patients and their relation to TERT promoter status in the tumor.
View article: Data from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Data from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Purpose:Human malignant pleural mesothelioma (MPM) is characterized by dismal prognosis. Consequently, dissection of molecular mechanisms driving malignancy is of key importance. Here we investigate whether activating mutations in the telo…
View article: Data from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>
Data from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> Open
Purpose: Malignant pleural mesothelioma (MPM) is an aggressive thoracic tumor type with limited treatment options and poor prognosis. The angiokinase inhibitor nintedanib has shown promising activity in the LUME-Meso phase II MPM tr…
View article: Supplementary Figure S5 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Figure S5 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Figure S5: Impact of TERT promoter status on sensitivity of MPM cell models against pharmacological telomerase and ETS factor inhibition.
View article: Supplementary Material and Methods from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Material and Methods from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Material and Methods
View article: Supplementary Table S1 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>
Supplementary Table S1 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> Open
Histological subtypes, drug sensitivitiy data and copy number changes of target RTKs in MPM cell lines
View article: Supplementary Table S6 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Table S6 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Table S6
View article: Supplementary Figure S5 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Figure S5 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Figure S5: Impact of TERT promoter status on sensitivity of MPM cell models against pharmacological telomerase and ETS factor inhibition.
View article: Supplementary Figure S2 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>
Supplementary Figure S2 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> Open
Expression of target RTKs of nintedanib in the P31 and SPC111 cells
View article: Supplementary Figure S3 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>
Supplementary Figure S3 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> Open
Impact of nintedanib on phosphorylation of target RTKs' downstream signaling
View article: Supplementary Figure S1 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>
Supplementary Figure S1 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> Open
Expression of PDGFRB and FGFR1 in MPM cell lines with different histological origin
View article: Supplementary Table S1 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>
Supplementary Table S1 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> Open
Histological subtypes, drug sensitivitiy data and copy number changes of target RTKs in MPM cell lines
View article: Supplementary Figure S1 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Figure S1 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Figure S1. Representative sequencing charts of the TERT promoter region harboring activating mutations.
View article: Supplementary Figure S2 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>
Supplementary Figure S2 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> Open
Expression of target RTKs of nintedanib in the P31 and SPC111 cells
View article: Supplementary Tables S1-S5 and S7-S9 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Tables S1-S5 and S7-S9 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Tables S1 to S9 with the exception of Supplementary Table S6
View article: Supplementary Figure S7 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Figure S7 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Figure S7. Coding variants detected in MPM cell cultures and their relation to TERT promoter status.